Table 3 Proportion of studies examining potential biomarkers for diagnosis that incorporated important study-design features
| Â | All diseases | SLE | RA | Other diseasesa |
|---|---|---|---|---|
| Â | n= 156 | n= 48 | n= 67 | n= 41 |
Study-design features | n (%) | n (%) | n (%) | n (%) |
Matched for age | 74 (47.4) | 30 (62.5) | 23 (34.3) | 21 (51.2) |
Matched for sex | 72 (46.1) | 28 (58.3) | 24 (35.8) | 20 (48.8) |
Matched for race | 51 (32.7) | 23 (47.9) | 20 (29.8) | 8 (19.5) |
Provided information on medications | 79 (50.6) | 34 (70.8) | 25 (37.3) | 20 (48.8) |
Controlled for treatment effects | 55 (35.3) | 25 (52.0) | 13 (19.4) | 17 (41.4) |
Reported use of accepted classification criteria | 140 (89.7) | 48 (100.0) | 52 (77.6) | 40 (97.6) |
Included patients with both early and late disease | 43 (27.6) | 16 (33.0) | 18 (26.9) | 9 (21.9) |
Included patients with both active and inactive disease | 58 (43.3) | 40 (83.3) | 15 (22.4) | 3 (15.8) |
Included disease controls | 61 (39.1) | 27 (56.2) | 16 (23.9) | 18 (43.9) |